Preclinical Triple-Humanized genO-hTFRC/hSA/hFcRn Mouse Model

Double-humanized genO‑hCD47/hSIRPα immunocompetent mice enable the efficacy assessment of anti-CD47/SIRPα.

‍

The genO‑hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 in fully immunocompetent mice.

The genO‑hCTLA-4/hLAG3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CTLA-4 and/or LAG3 in fully immunocompetent mice.

The genO-hICOS mouse enables the in vivo efficacy assessment of anti-ICOS-targeting agents in fully immunocompetent mice.

The genO-hOX40 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint OX40 in fully immunocompetent mice.

The genO‑hPD-1/hCTLA-4 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or CTLA-4 in fully immunocompetent mice.

The genO-hPD-1/hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1, GITR and/or GITRL in fully immunocompetent mice.

The genO‑hPD-1/hPD-L1 mouse model enables in vivo efficacy assessment and profiling of molecules targeting the human PD-1/PD-L1 axis in fully immunocompetent mice.

The genO‑hPD‑1/hTIM3 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or TIM3 in fully immunocompetent mice.

The genO‑hPD‑1/hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint PD-1 and/or VISTA in fully immunocompetent mice.

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the efficacy assessment of anti-CD3 and CD137 compounds.

Double-humanized genO-panhCD3/hCD28 immunocompetent mice enable the efficacy assessment of anti-CD3 and CD28 compounds.

‍

genO‑hCD137 immunocompetent mice enable the efficacy assessment of anti-CD137.

‍

The genO‑hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

The genO‑hCD39 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD39 in fully immunocompetent mice.

Double-humanized genO‑hFcγR/hFcRn mouse model to improve PK assessment of compounds with extended half-life through FcRn binders.

‍

The genO‑hGITR mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint GITR in fully immunocompetent mice.

The genO‑hGITR/hGITRL mouse model enables in vivo efficacy assessment and profiling of agonist and antagonist antibodies targeting human immune checkpoint GITR and/or GITRL in fully immunocompetent mice.

The genO‑hPD‑1 mouse enables the in vivo efficacy assessment and profiling of compounds targeting the human immune checkpoint PD-1 in fully immunocompetent mice

The genO‑hPD‑1/hLAG3 mouse model enables in vivo efficacy assessment and profiling of antibodies targeting human immune checkpoint PD-1 and/or LAG3 in fully immunocompetent mice.

Double humanized genO‑hSA/hFcRn mouse model as a cutting-edge platform for preclinical development of hSA and FcRn-oriented therapeutics.

This upgraded, immunocompromised RAG1^-/- version of our genO-hSA/hFcRn mouse model allows the assessment of compounds' half-life and anti-tumor efficacy in a human tumor model.

The fully immunocompetent genO‑hTFRC mouse model enables in vivo efficacy assessment and profiling of compounds targeting human TFRC (CD71, TfR1) and aiming to deliver therapeutic agents through the blood brain barrier.

Double-humanized genO-hTFRC/hFcγR mouse model to improve biodistribution and enable drug shuttling through the blood-brain barrier (BBB).

‍

The genO‑hVISTA mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint VISTA in fully immunocompetent mice.

The Pd-l1 Knockout colon carcinoma CT26 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

The genO-CT26-hCD39-LZ clonal cell line expresses high levels of human/mouse chimeric CD39, and forms solid tumors in vivo.

The genO-CT26-hCD47-LZ clonal cell line expresses human CD47, an optimized dual fusion reporter, luciferase-ZsGreen (LZ) and forms solid tumors in vivo.

genO-CT26-hEpCAM-LZ clonal cell line expresses high levels of human EpCAM, and forms solid tumors in vivo.

The humanized hPD-L1 syngeneic clonal colon carcinoma CT26 cell line expresses high levels of human PD-L1 and forms solid tumors in vivo.

genO-EL4-hCD19-LZ cells form tumors in syngeneic models, upon subcutaneous and systemic (i.v.) injection, in immunocompetent mice.

The genO-EL4-hCD20-LZ clonal cell line expresses high levels of human CD20.

The Pd-l1 Knockout colon adenocarcinoma MC38 cell line is invalidated for murine Pd-l1 and can be used for target validation and mechanistic studies.

The genO-MC38-hCD39-LZ cells homogeneously express human CD39 in vitro, and form infiltrated tumors in immunocompetent mice.

The genO-MC38-hPD-L1-LZ clonal cell line expresses high levels of  human PD-L1 and forms solid tumors in vivo. An optimized version of a  luciferase-ZsGreen (LZ) fusion protein is also stably expressed for in vivo imaging and ex vivo tracking.

The genO-MC38-hPD-L1-hFAP-LZ clonal cell line expresses human PD-L1, human FAP and an optimized dual fusion reporter, luciferase-ZsGreen (LZ)

The genO-MC38-hPD-L1-hHER2-LZ clonal cell line expresses high levels of human PD-L1  and human HER2.

The genO‑MC38-hPD-L1-hCD47-LZ clonal cell line expresses high levels of human PD-L1 and human CD47.